Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


EU gives green light for four new medicines

Written by | 1 May 2022 | Pharmacology

The European Medicine Agency’s key expert body – the Committee for Medicinal Products for Human Use (CHMP) – has recommended that four medicines be approved in the EU. This brings to 29 the number of new products authorised in 2022 by the end of April.

The newly approved medicines are:

  • Filsuvez (birch bark extract) for the treatment of epidermolysis bullosa.
  • Lunsumio (mosunetuzumab) which received a conditional marketing authorisationfor the treatment of relapsed or refractory (when treatment does not work) follicular lymphoma.
  • Tabrecta(capmatinib) for the treatment of advanced non-small cell lung cancer.
  • Pirfenidone AET (pirfenidone), a genetic medicine for the treatment of idiopathic pulmonary fibrosis.

In addition, the Committee recommended seven extensions of indication for medicines that are already authorised in the EU: BydureonElonvaKeytrudaNovoSevenRetsevmoTecentriq and Yescarta.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.